|  | Eribulin (n = 91) | Capecitabine (n = 79) | p |
---|---|---|---|---|
Age in years, n (%) | Median (range) | 56 (30–76) | 59 (36–74) | - |
≥60 | 34 (37) | 35 (44) | 0.43 | |
<60 | 57 (63) | 44 (56) | ||
Sex, n (%) | Male | 0 (0) | 0 (0) | - |
Female | 91 (100) | 79 (100) | ||
ECOG-PS, n (%) | 0 | 55 (60) | 43 (54) | 0.44 |
1 | 36 (40) | 35 (44) | ||
2 | 0 (0) | 1 (1) | ||
HR, n (%) | Positive | 71 (78) | 70 (89) | 0.1 |
Negative | 20 (22) | 9 (11) | ||
ER, n (%) | Positive | 68 (75) | 65 (82) | 0.27 |
Negative | 23 (25) | 14 (18) | ||
PgR, n (%) | Positive | 55 (60) | 52 (66) | 0.42 |
Negative | 36 (40) | 25 (32) | ||
NA | 0 (0) | 2 (3) | - | |
HER2, n (%) | Positive | 5 (6) | 2 (3) | 0.45 |
Negative | 85 (93) | 75 (95) | ||
NA | 1 (1) | 2 (3) | - | |
Triple-negative, n (%) | 17 (19) | 9 (11) | 0.21 | |
Surgical history, n (%) | Positive | 83 (91) | 72 (91) | 1.0 |
Negative | 8 (9) | 7 (9) | ||
Neoadjuvant/adjuvant chemotherapy, n (%) | Positive | 76 (84) | 63 (80) | 0.56 |
Negative | 15 (16) | 16 (20) | ||
Previous hormone therapy, n (%) | Positive | 63 (69) | 72 (91) | 0.001 |
Negative | 28 (31) | 7 (9) | ||
Previous anthracycline, n (%) | Positive | 85 (93) | 67 (85) | 0.08 |
Negative | 6 (7) | 12 (15) | ||
Previous taxane, n (%) | Positive | 88 (97) | 73 (92) | 0.31 |
Negative | 3 (3) | 6 (8) | ||
Previous chemotherapy regimens, n (%) | 0 | 11 (12) | 18 (23) | 0.001 |
1 | 29 (32) | 39 (49) | ||
2 | 51 (56) | 22 (28) | ||
Response, n (%) | PR | 14 (15) | 16 (20) | 0.018 |
SD | 43 (47) | 49 (62) | ||
PD | 34 (37) | 14 (18) | ||
Albumin, n (%) | ≥4.1 g/dL | 55 (60) | 51 (65) | 0.64 |
<4.1 g/dL | 36 (40) | 28 (35) | ||
LDH, n (%) | <222 U/L | 38 (42) | 48 (61) | 0.01 |
≥222 U/L | 53 (58) | 31 (39) | ||
CRP, n (%) | <0.15 mg/dL | 39 (43) | 46 (58) | 0.06 |
≥0.15 mg/dL | 52 (57) | 33 (42) | ||
NLR, n (%) | <3 | 65 (71) | 56 (71) | 1.0 |
≥3 | 26 (29) | 23 (29) | ||
ALC, n (%) | ≥1,500/µL | 31 (34) | 36 (46) | 0.16 |
<1,500/µL | 60 (66) | 43 (54) | ||
LMR, n (%) | ≥5 | 36 (40) | 45 (57) | 0.03 |
<5 | 55 (60) | 34 (43) | ||
PLR, n (%) | <250 | 73 (80) | 68 (86) | 0.41 |
≥250 | 18 (20) | 11 (14) |